Reuters logo
BRIEF-Second Cimzia Phase 3 trial meets co-primary efficacy endpoints
December 8, 2016 / 10:28 AM / 9 months ago

BRIEF-Second Cimzia Phase 3 trial meets co-primary efficacy endpoints

Dec 8 (Reuters) - Dermira Inc :

* Results from third and final phase 3 trial expected Q117

* Expect to report results from Cimpact in Q1 of 2017

* Second Cimzia (Certolizumab Pegol) phase 3 trial meets co-primary efficacy endpoints in patients with moderate-to-severe chronic plaque Psoriasis Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below